Livzon Pharmaceutical Group Inc.
000513
Hisse Senetlerindeki Sıralama
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Hisse Fiyatı
$3.90
Piyasa Değeri
$3.17B
Değişim (1 gün)
-3.49%
Değişim (1 yıl)
-25.88%
Ülke
CN
Ticaret Livzon Pharmaceutical Group Inc. (000513)
Kategori
Healthcare
Livzon Pharmaceutical Group Inc. (000513) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 20.23%
Livzon Pharmaceutical Group Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 20.23%'dir. 2024 yılı sonunda şirketin faaliyet marjı 24.08% idi.
Livzon Pharmaceutical Group Inc. için 2001 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 20.23% | -8.17% |
| 2025 | 22.03% | -8.51% |
| 2024 | 24.08% | 23.93% |
| 2023 | 19.43% | 4.41% |
| 2022 | 18.61% | -0.96% |
| 2021 | 18.79% | -20.95% |
| 2020 | 23.77% | 28.97% |
| 2019 | 18.43% | 28.16% |
| 2018 | 14.38% | -78.32% |
| 2017 | 66.32% | 475.69% |
| 2016 | 11.52% | 10.13% |
| 2015 | 10.46% | -0.76% |
| 2014 | 10.54% | -17.59% |
| 2013 | 12.79% | 4.84% |
| 2012 | 12.20% | -10.23% |
| 2011 | 13.59% | -28.25% |
| 2010 | 18.94% | -15.71% |
| 2009 | 22.47% | 36.02% |
| 2008 | 16.52% | -2.02% |
| 2007 | 16.86% | 123.61% |
| 2006 | 7.54% | -6.91% |
| 2005 | 8.10% | 2.40% |
| 2004 | 7.91% | -9.81% |
| 2003 | 8.77% | 22.66% |
| 2002 | 7.15% | -7.50% |
| 2001 | 7.73% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 19.41% | -99.04% |
DE
|
|
| 19.68% | -99.03% |
DE
|
|
| 10.52% | -99.48% |
JP
|
|
| 17.08% | -99.16% |
CH
|
|
| 22.93% | -98.87% |
IN
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.